目的 探究胺碘酮對于新生兒陣發(fā)性室上性心動過速（PSVT）的療效及安全性，為臨床治療提供依據(jù)。方法 回顧性分析2011年1月-2017年6月在梧州市工人醫(yī)院治療的PSVT新生兒病例48例，根據(jù)治療方法分為對照組和觀察組，每組24例。對照組患兒采用普羅帕酮、去乙酰毛花苷注射液等藥物積極對癥治療，觀察組患兒在對照組治療基礎上加用胺碘酮治療。分析比較兩組治療效果、心電圖轉(zhuǎn)歸、心肌標志物變化及不良反應發(fā)生情況。結(jié)果 治療后觀察組有效率為83.3%，高于對照組的62.5%，差異有統(tǒng)計學意義（P<0.05）。治療后觀察組心電圖轉(zhuǎn)歸有效率為95.8%，高于對照組的70.8%，差異有統(tǒng)計學意義（P<0.05）。治療前兩組患兒肌紅蛋白、肌鈣蛋白、肌酸激酶同工酶水平差異無統(tǒng)計學意義；治療后3種酶水平均有降低，同組治療前后比較差異有統(tǒng)計學意義（P<0.05）；且觀察組降低幅度大于對照組，差異有統(tǒng)計學意義（P<0.05）。兩組患兒均未發(fā)生嚴重不良反應。結(jié)論 胺碘酮在治療新生兒PSVT時療效確切，安全性較高，值得臨床推廣使用。

Objective To investigate the efficacy and safety of amiodarone in the treatment of paroxysmal supraventricular tachycardia (PSVT) in neonates and provide the basis for clinical treatment. Methods Forty-eight neonates with paroxysmal supraventricular tachycardia treated in our hospital from January 2011 to June 2017 were retrospectively analyzed. According to the treatment methods, they were divided into control group and observation group, with 24 cases in each group. Patients in the control group were given symptomatic treatment with drugs such as cardioversion and cedilanid, while patients in the observation group were treated with amiodarone on the basis of the control group. Analysis and comparison of two groups of treatment, ECG prognosis, changes in myocardial markers and adverse reactions. Results After treatment, the effective rate of the observation group was 83.3%, which was higher than that of the control group (62.5%), the difference was statistically significant (P<0.05). After treatment, the electrocardiogram outcome rate of the observation group was 95.8%, which was higher than that of the control group 70.8%, The difference was statistically significant (P<0.05). There was no significant difference in myoglobin, troponin and creatine kinase isozyme levels between the two groups before treatment. After treatment, the levels of three enzymes decreased, but the observation group decreased more than the control group, the difference was statistically significant (P<0.05). There was no serious adverse reaction in both groups. Conclusion Amiodarone in the treatment of neonatal PSVT exact effect, and has a high safety, worthy of clinical promotion.

R969